H.E.S.S. discovery of very-high-energy gamma-ray emission of PKS 1440-389

Blazars are the most abundant class of known extragalactic very-high-energy (VHE, E>100 GeV) gamma-ray sources. However, one of the biggest difficulties in investigating their VHE emission resides in their limited number, since less than 60 of them are known by now. In this contribution we report on H.E.S.S. observations of the BL Lac object PKS 1440-389. This source has been selected as target for H.E.S.S. based on its high-energy gamma-ray properties measured by Fermi-LAT. The extrapolation of this bright, hard-spectrum gamma-ray blazar into the VHE regime made a detection on a relatively short time scale very likely, despite its uncertain redshift. H.E.S.S. observations were carried out with the 4-telescope array from February to May 2012 and resulted in a clear detection of the source. Contemporaneous multi-wavelength data are used to construct the spectral energy distribution of PKS 1440-389 which can be described by a simple one-zone synchrotron-self Compton model.Comment: In Proceedings of the 34th International Cosmic Ray Conference (ICRC2015), The Hague, The Netherland

Detection potential to point-like neutrino sources with the NEMO-km3 telescope

The NEMO Collaboration is conducting an R&D activity towards the construction of a Mediterranean km3 neutrino telescope. In this work, we present the results of Monte Carlo simulation studies on the capability of the proposed NEMO telescope to detect and identify point-like sources of high energy muon neutrinos.Comment: To be published on BCN06 proceedings (Barcelona, July 4-7, 2006

Management of prostate cancer radiotherapy during the COVID-19 pandemic: A necessary paradigm change

Purpose: To adapt the management of prostate malignancy in response to the COVID-19 pandemic. Methods: In according to the recommendations of the European Association of Urology, we have developed practical additional document on the treatment of prostate cancer. Results: Low-Risk Group Watchful Waiting should be offered to patients >75 years old, with a limited life expectancy and unfit for local treatment. In Active Surveillance (AS) patients re-biopsy, PSA evaluation and visits should be deferred for up to 6 months, preferring non-invasive multiparametric-MRI. The active treatment should be delayed for 6–12 months. Intermediate-Risk Group AS should be offered in favorable-risk patients. Short-course neoadjuvant androgen deprivation therapy (ADT) combined with ultra-hypo-fractionation radiotherapy should be used in unfavorable-risk patients. High-Risk Group Neoadjuvant ADT combined with moderate hypofractionation should be preferred. Whole-pelvis irradiation should be offered to patients with positive lymph nodes in locally advanced setting. ADT should be initiated if PSA doubling time is < 12 months in radio-recurrent patients, as well as in low priority/low volume of metastatic hormone sensitive prostate cancer. If radiotherapy cannot be delayed, hypo-fractionated regimens should be preferred. In high priority class metastatic disease, treatment with androgen receptor-targeted agents should be offered. When palliative radiotherapy for painful bone metastasis is required, single fraction of 8 Gy should be offered. Conclusions: In Covid-19 Era, the challenge should concern a correct management of the oncologic patient, reducing the risk of spreading the virus without worsening tumor prognosis

Discovery of VHE gamma-rays from Centaurus A

We report the discovery of faint very high energy (VHE, E > 100 GeV) gamma-ray emission from the radio galaxy Centaurus A in deep observations performed with the H.E.S.S. experiment. A signal with a statistical significance of 5.0 sigma is detected from the region including the radio core and the inner kpc jets. The integral flux above an energy threshold of ~250 GeV is measured to be 0.8% of the flux of the Crab Nebula and the spectrum can be described by a power law with a photon index of 2.7 +/- 0.5_stat +/- 0.2_sys. No significant flux variability is detected in the data set. The discovery of VHE gamma-ray emission from Centaurus A reveals particle acceleration in the source to >TeV energies and, together with M 87, establishes radio galaxies as a class of VHE emitters.Comment: 4 pages, 3 figures, submitted as proceeding to the 44th Recontre de Moriond "Very High Energy Phenomena in the Universe", contains an updated SED including the recent Fermi dat

Toxicity after moderately hypofractionated versus conventionally fractionated prostate radiotherapy: A systematic review and meta-analysis of the current literature

Background: Moderately hypofractionated radiotherapy (RT) currently represents the standard RT approach for all prostate cancer (PCa) risk categories. We performed a systematic review and meta-analysis of available literature, focusing on acute and late genitourinary (GU) and gastrointestinal (GI) adverse events (AEs) of moderate hypofractionation for localized PCa. Materials and methods: Literature search was performed and two independent reviewers selected the records according to the following Population (P) Intervention (I) Comparator (C) and Outcomes (O) (PICO) question: “In patients affected by localized PCa (P), moderately hypofractionated RT (defined as a treatment schedule providing a single dose per fraction of 3–4.5 Gy) (I) can be considered equivalent to conventionally fractionated RT (C) in terms of G > 2 GI and GU acute and late adverse events (O)?”. Bias assessment was performed using Cochrane Cochrane Collaboration's Tool for Assessing Risk of Bias. Results: Thirteen records were identified and a meta-analysis was performed. Risk of acute GI and GU > 2 adverse events in the moderately hypofractionated arm was increased by 9.8 % (95 %CI 4.8 %–14.7 %; I2 = 57 %) and 1.5 % (95 % CI -1.5 %-4.4 %; I2 = 0%), respectively. Discussion: Overall, majority of trials included in our meta-analysis suggested that moderately hypofractionated RT is equivalent, in terms of GI and GU adverse events, to conventional fractionation. Pooled analysis showed a trend to increased GI toxicity after hypofractionated treatment, but this might be related to dose escalation rather than hypofractionation